0000000000269663

AUTHOR

Dewi Vernerey

showing 3 related works from this author

Erratum to: Development and validation of the FRAGIRE tool for assessment an older person’s risk for frailty

2016

Background Frailty is highly prevalent in elderly people. While significant progress has been made to understand its pathogenesis process, few validated questionnaire exist to assess the multidimensional concept of frailty and to detect people frail or at risk to become frail. The objectives of this study were to construct and validate a new frailty-screening instrument named Frailty Groupe Iso-Ressource Evaluation (FRAGIRE) that accurately predicts the risk for frailty in older adults. Methods A prospective multicenter recruitment of the elderly patients was undertaken in France. The subjects were classified into financially-helped group (FH, with financial assistance) and non-financially …

Older personGerontologyRehabilitationFrailtybusiness.industryGeriatrics gerontologymedicine.medical_treatmentPublished ErratumMEDLINEEvaluation toolLoss of autonomy03 medical and health sciencesElderly0302 clinical medicinemedicine030212 general & internal medicineGeriatrics and Gerontologybusiness030217 neurology & neurosurgeryResearch ArticleBMC Geriatrics
researchProduct

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation …

2015

Purpose The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free survival (DFS) and 6-year overall survival (OS) benefit of adjuvant oxaliplatin in stage II to III resected colon cancer. This update presents 10-year OS and OS and DFS by mismatch repair (MMR) status and BRAF mutation. Methods Survival actualization after 10-year follow-up was performed in 2,246 patients with resected stage II to III colon cancer. We assessed MMR status and BRAF mutation in 1,008 formalin-fixed paraffin-embedded specimens. Results After a median follow-up of 9.5 years, 10-year OS rates in the bolus/…

AdultMaleProto-Oncogene Proteins B-rafOncologyCancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentPopulationLeucovorinGlutamic AcidKaplan-Meier EstimateDNA Mismatch RepairDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsOdds RatiomedicineHumansStage (cooking)Infusions IntravenouseducationAgedNeoplasm Stagingeducation.field_of_studyChemotherapybusiness.industryHazard ratioValineMiddle AgedPrognosismedicine.diseasedigestive system diseasesSurgeryOxaliplatinTreatment OutcomeOncologyChemotherapy AdjuvantFluorouracilColonic NeoplasmsInjections IntravenousMutationFemaleFluorouracilbusinessAdjuvantFollow-Up Studiesmedicine.drugJournal of Clinical Oncology
researchProduct

Development and validation of the FRAGIRE tool for assessment an older person’s risk for frailty

2016

International audience; Background: Frailty is highly prevalent in elderly people. While significant progress has been made to understand its pathogenesis process, few validated questionnaire exist to assess the multidimensional concept of frailty and to detect people frail or at risk to become frail. The objectives of this study were to construct and validate a new frailty-screening instrument named Frailty Groupe Iso-Ressource Evaluation (FRAGIRE) that accurately predicts the risk for frailty in older adults.Methods: A prospective multicenter recruitment of the elderly patients was undertaken in France. The subjects were classified into financially-helped group (FH, with financial assista…

MaleGerontologyMultivariate statisticsmedicine.medical_treatmentlcsh:GeriatricsLogistic regression0302 clinical medicineElderlySurveys and QuestionnairesPrevalenceadultsProspective Studies030212 general & internal medicineelderly-peopleAged 80 and overeducation.field_of_studyRehabilitationFrailty[SDV.MHEP.GEG] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyPrognosisEvaluation tool3. Good healthLoss of autonomyFemaleFranceErratummedicine.medical_specialtyPsychometricsFrail ElderlySeparation (statistics)Population[ SDV.MHEP.GEG ] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyRisk AssessmentSensitivity and Specificity03 medical and health sciencesCronbach's alphamedicineHumanseducationGeriatric AssessmentAgedmodelbusiness.industryUnivariateReproducibility of ResultsConfidence intervallcsh:RC952-954.6Logistic ModelsPhysical therapyGeriatrics and Gerontologybusiness030217 neurology & neurosurgerydementia
researchProduct